Longboard Pharmaceuticals, Inc. (LBPH)
- Previous Close
33.33 - Open
33.29 - Bid 28.65 x 200
- Ask 37.26 x 200
- Day's Range
33.16 - 40.40 - 52 Week Range
3.60 - 40.48 - Volume
1,630,105 - Avg. Volume
637,614 - Market Cap (intraday)
1.443B - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-2.16 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
65.88
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
www.longboardpharma.comRecent News: LBPH
View MorePerformance Overview: LBPH
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LBPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LBPH
View MoreValuation Measures
Market Cap
1.30B
Enterprise Value
997.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.41
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.04%
Return on Equity (ttm)
-36.71%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-64.74M
Diluted EPS (ttm)
-2.16
Balance Sheet and Cash Flow
Total Cash (mrq)
304.87M
Total Debt/Equity (mrq)
1.31%
Levered Free Cash Flow (ttm)
-33.76M